Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities
Journal of Cell Science · 15.07.2024 · 137 (14)
DOI: 10.1242/jcs.261723 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cell Science, online erschienen am 22.07.2024. Verfasst von David D Schlaepfer und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic O…. Hauptthemen laut MEDLINE: Focal Adhesion Protein-Tyrosine Kinases, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Juselius Foundation, University of California, NCI NIH HHS.
Abstract (Originalsprache)
Focal adhesion kinase (FAK; encoded by PTK2) was discovered over 30 years ago as a cytoplasmic protein tyrosine kinase that is localized to cell adhesion sites, where it is activated by integrin receptor binding to extracellular matrix proteins. FAK is ubiquitously expressed and functions as a signaling scaffold for a variety of proteins at adhesions and in the cell cytoplasm, and with transcription factors in the nucleus. FAK expression and intrinsic activity are essential for mouse development, with molecular connections to cell motility, cell survival and gene expression. Notably, elevated FAK tyrosine phosphorylation is common in tumors, including pancreatic and ovarian cancers, where it is associated with decreased survival. Small molecule and orally available FAK inhibitors show on-target inhibition in tumor and stromal cells with effects on chemotherapy resistance, stromal fibrosis and tumor microenvironment immune function. Herein, we discuss recent insights regarding mechanisms of FAK activation and signaling, its roles as a cytoplasmic and nuclear scaffold, and the tumor-intrinsic and -extrinsic effects of FAK inhibitors. We also discuss results from ongoing and advanced clinical trials targeting FAK in low- and high-grade serous ovarian cancers, where FAK acts as a master regulator of drug resistance. Although FAK is not known to be mutationally activated, preventing FAK activity has revealed multiple tumor vulnerabilities that support expanding clinical combinatorial targeting possibilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California, San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, 3855 Health Sciences Dr., La Jolla, CA 92098, USA.
ORCID-Profile: David D Schlaepfer, Marjaana Ojalill, Dwayne G Stupack
Förderung
- Sigrid Juselius Foundation
- University of California
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Schlaepfer, D. D., Ojalill, M., & Stupack, D. G. (2024). Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities. Journal of Cell Science, 137(14). https://doi.org/10.1242/jcs.261723
Vancouver
Schlaepfer DD, Ojalill M, Stupack DG. Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities. Journal of Cell Science. 2024;137(14). doi:10.1242/jcs.261723
BibTeX
@article{Schlaepfer2024,
author = {Schlaepfer, David D and Ojalill, Marjaana and Stupack, Dwayne G},
title = {Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities},
journal = {Journal of Cell Science},
year = {2024},
volume = {137},
number = {14},
doi = {10.1242/jcs.261723}
}
EUVIMED